2022年11月19日 · Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker. We evaluated sFRα...

2023年12月6日 · Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in...

2023年2月1日 · Due to the ability of folate conjugates (folic acid, anti-FR antibodies) to be endocytosed into cancer cells via receptor-mediated endocytosis, the FR is a popular target in drug delivery systems for FR-positive tumors (Table 1). As a result, there is diversity in targeted FR therapies, which include: nanoparticle therapies, folate-conjugated ...

2020年3月9日 · In this Review, we describe the current status of research into FRα in cancer, including data from several late-phase clinical trials involving FRα-targeted therapies, and the use of new...

We describe examples of past and present treatment approaches and promising therapeutic avenues, with specific focus on monoclonal antibodies for ovarian, lung and breast cancer, as examples of FRα-positive malignancies.

The folate receptor (FR) is a recognised biomarker for tumour cells due to its overexpression on a large number of tumours. Consequently, the FR has been exploited by many diagnostic and therapeutic tools to allow targeted delivery to, and imaging of, cancer cells.

2023年1月16日 · In November 2022, the FDA granted an accelerated approval for the use of mirvetuximab soravtansine-gynx (Elahere) to treat adults with FRα-positive, platinum-resistant epithelial ovarian,...

Folate targeting is a method utilized in biotechnology for drug delivery purposes. This Trojan Horse process, which was created by Drs. Christopher P. Leamon and Philip S. Low, involves the attachment of the vitamin, folate (folic acid), to a molecule/drug to form a "folate conjugate". [1] .

2023年11月26日 · FR plays a significant role in DNA synthesis, cell proliferation, DNA repair, and intracellular signaling, all of which are essential for tumorigenesis. FR is more prevalent in cancer cells compared to normal tissues, which makes it an excellent target for oncologic therapeutics.

In the present study, the aim was to characterize these FR-positive cell lines in vitro and in vivo. The relative FR-expression level and the ability to bind folate radioconjugates were investigated in cultured cells. The most promising cancer cell lines were …